Serine 329 of the μ-opioid receptor interacts differently with agonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 924-930

  Pil, Joost ^a   Tytgat, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE DERIVATIVE; BETA HYDROXYFENTANYL; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; G PROTEIN COUPLED RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; MEMBRANE PROTEIN; MORPHINE; MU OPIATE RECEPTOR; PROTEIN GIRK1; PROTEIN GIRK2; R004333; RGS PROTEIN; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE MUTATION; HYDROGEN BOND; HYDROPHILICITY; MOLECULAR CLONING; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; ELECTROPHYSIOLOGY; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; OOCYTES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, OPIOID, MU; SERINE; TRANSFECTION; XENOPUS LAEVIS;

EID: 0037369805     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.040113     Document Type: Article

References (38)

1. Akil H, Meng F, Mansour A, Thompson R, Xie GX, and Watson S (1996) Cloning and characterization of multiple opioid receptors. NIDA Res Monogr 161:127-140.
2. 3H]β-funaltrexamine covalent binding in the cloned rat μ-opioid receptor. J Biol Chem 271:21422-21429.
3. + channels. Proc Natl Acad Sci USA 94:10461-10466.
4. Filizola M, Laakkonen L, and Loew GH (1999) 3D modeling, ligand binding and activation studies of the cloned mouse δ, μ, and κ opioid receptors. Protein Eng 12:927-942.
5. Habibi-Nezhad B, Hanifian M, and Mahmoudian M (1996) Computer-aided receptor modelling of human opioid receptors: (μ, κ and δ). J Mol Model 2:362-369.
6. Kanematsu K and Sagara T (2001) An approach to the rational design of opioid receptor ligands: Non-narcotic κ-opioid receptor ligand KT-95 free from euphoria and/or dysphoria. Curr Med Chem 1:1-25.
7. Kieffer BL (1995) Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 15:615-635.
8. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, and Yamamura HI (1995) Molecular biology and pharmacology of cloned opioid receptors. FASEB J 9:516-525.
9. + channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem Biophys Res Commun 208:1166-1173.
10. + channels are activated by Gβγ subunits and function as heteromultimers. Proc Natl Acad Sci USA 92:6542-6546.
11. Krieg PA and Melton DA (1984) Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res 12:7057-7070.
12. Krystek SR Jr, Patel PS, Rose PM, Fisher SM, Kienzle BK, Lach DA, Liu EC, Lynch JS, Novotny J, and Webb ML (1994) Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. J Biol Chem 269:12383-12386.
13. Law PY and Loh HH (1999) Regulation of opioid receptor activities. J Pharmacol Exp Ther 289:607-624.
14. Law PY, Wong YH, and Loh HH (1999) Mutational analysis of the structure and function of opioid receptors. Biopolymers 51:440-455.
15. 147 in the third transmembrane helix of the rat μ opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci 65:175-185.
16. + channel determined by construction of multimeric cDNAs. Neuron 9:861-871.
17. Mansour A, Taylor LP, Fine JL, Thompson RC, Hoversten MT, Mosberg HI, Watson SJ, and Akil H (1997) Key residues defining the μ-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem 68:344-353.
18. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature (Lond) 383:819-823.
19. McFadyen IJ, Houshyar H, Liu-Chen LY, Woods JH, and Traynor JR (2000) The Steroid 17α-acetoxy-6-dimethylaminomethyl-21-fluoro -3-ethoxy-pregna-3,5-dien-20-one (SC17599) is a selective μ-opioid agonist: implications for the μ-opioid pharmacophore. Mol Pharmacol 58:669-676.
20. Meng F, Hoversten MT, Thompson RC, Taylor L, Watson SJ, and Akil H (1995) A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ opioid receptors. Potential role of extracellular domains. J Biol Chem 270:12730-12736.
21. Minami M, Onogi T, Nakagawa T, Katao Y, Aoki Y, Katsumata S, and Satoh M (1995) DAMGO, a μ-opioid receptor selective ligand, distinguishes between μ- and κ-opioid receptors at a different region from that for the distinction between μ- and δ-opioid receptors. FEBS Lett 364:23-27.
22. Minami M and Satoh M (1995) Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 23:121-145.
23. Mo Y, Subramanian G, Gao J, and Ferguson DM (2002) Cation-π interactions: an energy decomposition analysis and its implication in δ-opioid receptor-ligand binding. J Am Chem Soc 124:4832-4837.
24. Onogi T, Minami M, Katao Y, Nakagawa T, Aoki Y, Toya T, Katsumata S, and Satoh M (1995) DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ-and δ-opioid receptors around their first extracellular loops. FEBS Lett 357:93-97.
25. 230 residue of the μ-opioid receptor in the potency of various opioid agonists. Br J Pharmacol 134:496-506.
26. Pogozheva ID, Lomize AL, and Mosberg HI (1998) Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys J 75:612-634.
27. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, and Reisine T (1994) Pharmacological characterization of the cloned κ-, δ- and μ-opioid receptors. Mol Pharmacol 45:330-334.
28. Seki T, Minami M, Nakagawa T, Ienaga Y, Morisada A, and Satoh M (1998) DAMGO recognizes four residues in the third extracellular loop to discriminate between μ-and κ-opioid receptors. Eur J Pharmacol 350:301-310.
29. Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, and Surratt CK (1997) Naloxone activation of μ-opioid receptors mutated at a histidine residue lining the opioid binding cavity. Mol Pharmacol 52:983-992.
30. Strahs D and Weinstein H (1997) Comparative modeling and molecular dynamics studies of the δ, κ and μ opioid receptors. Protein Eng 10:1019-1038.
31. Subramanian G, Paterlini MG, Portoghese PS, and Ferguson DM (2000) Molecular docking reveals a novel binding site model for fentanyl at the μ-opioid receptor. J Med Chem 43:381-391.
32. Tang Y, Chen KX, Jiang HL, Wang ZX, Ji RY, and Chi ZQ (1996) Molecular modeling of μ opioid receptor and its interaction with ohmefentanyl. Zhongguo Yao Li Xue Bao 17:156-160.
33. Ulens C, Daenens P, and Tytgat J (2000a) Changes in GIRK1/GIRK2 deactivation kinetics and basal activity in the presence and absence of RGS4. Life Sci 67:2305-2317.
34. Ulens C, Van Boven M, Daenens P, and Tytgat J (2000b) Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in μ-opioid receptor selectivity. J Pharmacol Exp Ther 294:1024-1033.
35. 319 of the rat μ-opioid receptor in binding of μ-selective ligands. Synapse 32:23-28.
36. 332(7.49) in TMH 7 of the μ opioid receptor. FEBS Lett 447:318-324.
37. Xue JC, Chen C, Zhu J, Kunapuli SP, de Riel JK, Yu L, and Liu-Chen LY (1995) The third extracellular loop of the μ opioid receptor is important for agonist selectivity. J Biol Chem 270:12977-12979.
38. Zadina JE, Hackler L, Ge LJ, and Kastin AJ (1997) A potent and selective agonist for the μ-opiate receptor. Nature (Lond) 386:499-502.